NCT06341309尚未招募1 期
Exploratory Study of Irinotecan Liposomes Combined With Bevacizumab in Maintenance Therapy of Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- Progression free survival -1
研究概览
简要总结
To evaluate the progression-free survival (PFS1), objective response rate (ORR), disease control rate (DCR), progression-free survival from first-line treatment initiation (PFS2), overall survival (OS), and safety of irinotecan liposome combined with bevacizumab in patients with advanced metastatic colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18~85 years old.
- •Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma.
- •pMMR or MSS.
- •CR, PR, or SD (according to RECIST v1.1 criteria) achieved after 12-16 weeks of intensive treatment with a first-line chemotherapy regimen containing irinotecan/fluorouracil or a three-drug chemotherapy regimen containing oxaliplatin/irinotecan/fluorouracil plus bevacizumab.
- •If previously received neoadjuvant or adjuvant therapy, the time interval between initiation of systemic first-line therapy and the date of last dosing must be at least 6 months.
- •ECOG 0~1, patients ≥75 years old need an ECOG score of
- •Normal bone marrow and organ function: ① Neutrophils (ANC) ≥1.5×10^9/L, platelets (PLT) ≥75×10^9/L, hemoglobin (Hb) ≥85g/L, albumin (ALB) ≥30 g/L, white blood cells (WBC) ≥3.0×10^9/L, and no bleeding tendency; ② AST, ALT and alkaline phosphatase (ALP) were all ≤2.5× upper limit of normal range (ULN), and ≤5×ULN when liver metastases occurred; The total bilirubin level doesn't exceed the upper limit of the agency's normal range; Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60 ml/min (calculated according to Cockroft-Gault).
- •Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form.
排除标准
- •Known or suspected central nervous system metastasis.
- •Had received surgery or other treatment for tumors other than intensive treatment (including chemotherapy, radiotherapy, research treatment, etc., within 4 weeks prior to enrollment, if the interval between the current treatment was longer than 5 drug half-lives, could be included).
- •Previous treatment-related toxicity did not return to NCI-CTCAE v5.0 I or below (except for alopecia, peripheral neuropathy).
- •The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment.
- •The presence of severe gastrointestinal dysfunction or gastrointestinal perforation, intraperitoneal abscess, and fistula.
- •Intestinal obstruction, signs and symptoms of intestinal obstruction, or the stent has been previously implanted and the stent has not been removed before the screening period.
- •Interstitial lung disease.
- •Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding).
- •Patients with fluid accumulation that couldn't reach a stable state but small amount of ascites on imaging without clinical symptoms could be enrolled.
- •Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc.
- •Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer.
- •Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding.
- •The researchers didn't consider it appropriate to participate in this study.
研究组 & 干预措施
irinotecan liposome injection combined with bevacizumab
Experimental
Patients will be treated with irinotecan liposome injection combined with bevacizumab. Treatment until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
干预措施: Irinotecan Liposome (Drug)
irinotecan liposome injection combined with bevacizumab
Experimental
Patients will be treated with irinotecan liposome injection combined with bevacizumab. Treatment until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Progression free survival -1
时间窗: From initial medication to the date of first documented progression or end of medication, whichever came first . Assessed up to 18 months.
The time from initiation of maintenance therapy to first recording of PD or death, whichever occurs first. To investigate antitumor efficacy of study.
次要结局
- Progression free survival -2(The time from the start of first-line treatment to the maintenance of PD treatment or death, whichever occurs first. Assessed up to 24 months.)
- Objective response rate(From initial medication to the date of first documented progression or end of medication, whichever came first. Assessed up to 18 months)
- Disease control rate(From initial medication to the date of first documented progression or end of medication , assessed up to 18 months.)
- Overall survival(From initial medication to the date of death from any cause, Assessed up to 30 months.)
- Incidence of adverse events and severity of adverse events as assessed by CTCAE 5.0(Assessed up to 6 months.)
研究者
相似试验
招募中
2 期
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT06341296West China Hospital86
尚未招募
2 期
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric CancerGastric CancerNCT06437678Zhejiang Cancer Hospital50
招募中
4 期
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung CancerSmall Cell Lung CancerNCT06467786Tang-Du Hospital24
尚未招募
1 期
Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid TumorsSolid Tumor CancerNCT06710821Yizhuo Zhang40
进行中（未招募）
1 期
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerMetastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Malignant Digestive System NeoplasmMetastatic Pancreatic AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7NCT03337087Academic and Community Cancer Research United18